VRC Vaccine Research Studies
Clinical Studies Archive
Studies Closed to Accrual
VRC Clinical Trials Related to Development of Vaccines for Prevention of HIV
VRC 001 (01-I-0079):
"Evaluation of an HIV-1 DNA Vaccine Encoding a Modified Gag-Pol Protein in Uninfected Adult Volunteers"
VRC 004 (03-I-0022):
A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA009-00-VP, in Uninfected Adult Volunteers
VRC 006 (04-I-0172):
A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Multiclade HIV-1 Adenoviral Vector Vaccine, VRC-HIVADV014-00-VP, in Uninfected Adult Volunteers
VRC 007 (04-I-0254):
A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a 6-Plasmid Multiclade HIV-1 DNA Vaccine, VRC-HIVDNA016-00-VP, in Uninfected Adult Volunteers
VRC 008 (05-I-0148):
A Phase I Clinical Trial of a Prime-Boost HIV-1 Vaccination Schedule: Multiclade DNA Vaccine, VRC-HIVDNA016-00-VP, Followed by Multiclade Adenoviral Vector Vaccine, VRC-HIVADV014-00-VP, in Uninfected Adult Volunteers
VRC 009 (05-I-0081):
A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Booster Dose of a Recombinant Multiclade HIV-1 Adenoviral Vector Vaccine, VRC-HIVADV014-00-VP, in Uninfected Subjects who were Previously Immunized with VRC-HIVDNA009-00-VP in VRC 004 (03-I-0022)
VRC 010 (05-I-0140):
A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Booster Dose of a Recombinant Multiclade HIV-1 Adenoviral Vector Vaccine, VRC-HIVADV014-00-VP, in Uninfected Subjects who were Previously Immunized with VRC-HIVDNA016-00-VP in VRC 007 (04-I-0254)
VRC 011 (06-I-0149):
A Phase I Clinical Trial of Intramuscular, Subcutaneous and Intradermal Administration of an HIV-1 Multiclade DNA Vaccine, VRC-HIVDNA016-00-VP, and an HIV-1 Multiclade Adenoviral Vector Vaccine, VRC-HIVADV014-00-VP, in Uninfected Adult Volunteers
VRC 012 (07-I-0167):
A Phase I Clinical Trial of the Safety and Immunogenicity of an HIV-1 Adenoviral Vector Serotype 35 Vaccine, VRC-HIVADV027-00-VP (rAd35-EnvA): Dose Escalation as a Single Agent and Prime-Boost Schedules with an HIV-1 Adenoviral Vector Serotype 5 Vaccine, VRC-HIVADV038-00-VP (rAd5-EnvA), in Uninfected Adults
VRC 015 (08-I-0171):
A Phase I, Open-Label Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of a Multiclade Recombinant HIV-1 Adenoviral Vector Vaccine, VRC-HIVADV014-00-VP, in Uninfected Adults Randomized to Needle or Biojector Methods of Intramuscular Injection
VRC Clinical Trials Related to Development of Vaccines for Treatment of HIV
VRC 100 (03-I-0079):
Screening HIV-Infected Subjects for Vaccine Research Studies
VRC 101 (06-I-0056):
A Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-Boost Vaccination Schedule of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, followed by a Recombinant Multiclade HIV-1 Adenoviral Vector Vaccine, VRC-HIVADV014-00-VP, in HIV-Infected Adult Volunteers
VRC Clinical Trials Related to Vaccines for Biodefense and Emerging Pathogens
VRC 300 (03-I-0285):
Screening of Healthy Volunteers for Clinical Trials of Investigational Vaccines to Prevent Infectious Diseases
Smallpox Vaccine Studies
VRC 201 (02-I-0316):
A Phase I/II Clinical Trial of Modified Vaccinia Virus Ankara (MVA) to Evaluate its Safety, Dosing Schedule, Immunogenicity and Protective Efficacy Against Dryvax Challenge in Vaccinia-Naive Individuals
VRC 203 (03-I-0087):
A Phase I/II Clinical Trial of Modified Vaccinia Virus Ankara (MVA) to Evaluate its Safety, Immunogenicity and Protective Efficacy Against Dryvax Challenge in Vaccinia-Immune Individuals
Ebola Vaccine Studies
VRC 204 (04-I-0028):
A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiple Strain Ebola DNA Plasmid Vaccine, VRC-EBODNA012-00-VP, in Adult Volunteers
VRC 205 (06-I-0237):
A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Ebola Adenoviral Vector Vaccine, VRC-EBOADV018-00-VP, in Healthy Adults
VRC 206 (08-I-0065):
A Phase I Study to Evaluate the Safety and Immunogenicity of an Ebola DNA Plasmid Vaccine, VRC-EBODNA023-00-VP, and a Marburg DNA Vaccine, VRC-MARDNA025-00-VP, in Healthy Adults
SARS Vaccine Studies
VRC 301 (05-I-0056):
A Phase I Study of the Safety and Immunogenicity of a SARS Recombinant DNA Plasmid Vaccine, VRC-SRSDNA015-00-VP, in Healthy Adult Volunteers
West Nile Virus Vaccine Studies
VRC 302 (05-I-0126):
A Phase I Study of the Safety and Immunogenicity of a West Nile Virus Recombinant DNA Plasmid Vaccine, VRC-WNVDNA017-00-VP, in Healthy Adult Volunteers
VRC 303 (06-I-0110):
A Phase I Study of the Safety and Immunogenicity of a West Nile Virus Recombinant DNA Plasmid Vaccine, VRC-WNVDNA020-00-VP, in Healthy Adult Subjects
Influenza Vaccine Studies
VRC 304 (07-I-0042):
A Phase I Study of the Safety and Immunogenicity of a Recombinant DNA Plasmid Vaccine (VRC-AVIDNA036-00-VP), Encoding for the Influenza Virus H5 Hemagglutinin Protein in Healthy Adults
VRC 305 (07-I-0172):
A Phase I Open-Label Study of the Safety and Immunogenicity of a Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for the Influenza Virus H5 Hemagglutinin Protein Administered Intradermally in Healthy Adults
VRC 306 (09-I-0012):
An Open-Label, Randomized Phase I Study in Healthy Adults of Four Prime-Boost Schedules with Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc), Administered Alone or Following Recombinant DNA Plasmid (H5) Vaccine, VRC-AVIDNA036-00-VP (VRC, NIAID)
VRC 307 (09-I-0090):
A Double-Blind, Randomized Phase I Study of the Safety and Immunogenicity of a Prime-Boost Schedule of the Investigational DNA Trivalent Influenza Vaccine, VRC-FLUDNA047-00-VP, Followed by the 2008/2009 Seasonal Influenza Trivalent Inactivated Vaccine (TIV) Compared to TIV Alone in Healthy Adults Ages 18-50 and 51-70 Years
VRC 308 (09-I-0204):
An Open-Label Phase I Study of the Safety and Immunogenicity of an Investigational H1 DNA Influenza Vaccine, VRC-FLUDNA057-00-VP, in Healthy Adults 18-70 Years Old
VRC 309 (10-I-0004):
A Multi-Center, Open-Label, Randomized Phase I Study of an Investigational Influenza DNA Vaccine Followed by 2009/2010 Seasonal Influenza Trivalent Inactivated Vaccine (TIV) Compared to Two Injections of TIV in Adults 45-70 Years
VRC 310 (10-I-0069):
An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals with Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc), Administered Alone or Following Recombinant DNA Plasmid (H5) Vaccine, VRC-AVIDNA036-00-VP (VRC, NIAID)
VRC 311 (12-I-0041):
Phase 1, Open Label, Dose-Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of a Virus-Like Particle (VLP) Chikungunya Vaccine in Healthy Adults
VRC Protocols to Obtain Laboratory Samples for Vaccine and Immunology Research
VRC PAN (02-I-0066):
Studies of Specific Immune Responses in Human Peripheral Blood Cells in HIV-Infected and HIV-Uninfected Volunteers
back to top
